enrollment penalty, and IRMAA determinations.

Section 1871(c) of the Act requires that we publish a list of all Medicare manual instructions, interpretive rules, statements of policy, and guidelines of general applicability not issued as regulations at least every 3 months in the **Federal Register**.

#### II. Format for the Quarterly Issuance Notices

This quarterly notice provides the specific updates to the OCPM that have occurred in the 3-month period. A hyperlink to the available chapters on the OMHA Web site is provided below. The OMHA Web site contains the most current, up-to-date chapters and revisions to chapters, and will be available earlier than we publish our quarterly notice. We believe the OMHA Web site list provides more timely access to the current OCPM chapters for those involved in the Medicare claim, organization and coverage determination and entitlement appeals processes. We also believe the Web site offers the public a more convenient tool for real time access to current OCPM provisions. In addition, OMHA has a listserv to which the public can subscribe to receive immediate notification of any updates to the OMHA Web site. This listserv avoids the need to check the OMHA Web site, as update notifications are sent to subscribers as they occur. If accessing the OMHA Web site proves to be difficult, the contact person listed above can provide the information.

#### III. How To Use the Notice

This notice lists the OCPM chapters and subjects published during the quarter covered by the notice so the reader may determine whether any are of particular interest. We expect this notice to be used in concert with the previously published notice. The OCPM can be accessed at <a href="http://www.hhs.gov/omha/OMHA\_Case\_Processing\_Manual/index.html">http://www.hhs.gov/omha/OMHA\_Case\_Processing\_Manual/index.html</a>.

## IV. OCPM Releases for July Through September 2015

The OCPM is used by OMHA adjudicators and staff to administer the OMHA program. It offers day-to-day operating instructions, policies, and procedures based on statutes and regulations, and OMHA directives.

The following is a list and description of new and revised OCPM provisions, and the subject matter, that have been released in the covered 3-month period. The full text of current OCPM provisions is available on our Web site

at http://www.hhs.gov/omha/OMHA Case Processing Manual/index.html.

#### OCPM Division I: General Matters

Chapter 4, Parties. This new chapter describes who qualify as parties to the ALJ hearing and review process under the applicable authorities to guide OMHA ALJs and support staff in ensuring those filing requests for hearing and requests for review with OMHA have standing to pursue appeals, and notices and other correspondence are sent to the appropriate individuals and entities in accordance with the authorities.

Chapter 5, Representatives. This new chapter describes the roles and responsibilities of party representatives in the ALJ hearing and review process, as well as the requirements to substantiate that an individual is authorized or appointed to act as a party representative under the applicable authorities.

Chapter 6, CMS and CMS Contractor Roles. This new chapter describes the roles and responsibilities of CMS and its contractors in the ALJ hearing and review process, including under what conditions and how CMS or a contractor may participate in the process, including at oral hearings before OMHA ALJs, in accordance with the applicable authorities.

## OCPM Division II: Part A/B Claim Determinations

Chapter 3, Procedural Screening. This chapter has been updated to correct a typographical error. No substantive changes were made to the chapter.

Dated:  $_{\rm November~17,~2015}$ .

## Nancy J. Griswold,

Chief Administrative Law Judge, Office of Medicare Hearings and Appeals.

[FR Doc. 2015–30044 Filed 11–24–15; 8:45 am]

BILLING CODE 4152-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel AIDS Research Centers on Mental Health and HIV/ AIDS (P30).

Date: December 2, 2015.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: David W. Miller, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive BLVD, Room 6140, MSC 9608, Bethesda, MD 20892–9608, 301–443– 9734, millerda@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: November 18, 2015.

#### Carolyn A. Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–29942 Filed 11–24–15; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Pathogenesis of Rare Diseases.

*Date:* November 20, 2015–November 20, 2016.

Time: 2:00 p.m. to 4:00 p.m.